<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Georgala,A.</style></author><author><style face="normal" font="default" size="100%">Vekemans,M.</style></author><author><style face="normal" font="default" size="100%">Husson,M.</style></author><author><style face="normal" font="default" size="100%">Meuleman,N.</style></author><author><style face="normal" font="default" size="100%">H. Beguin</style></author><author><style face="normal" font="default" size="100%">Nolard,N.</style></author><author><style face="normal" font="default" size="100%">M. Aoun</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Zygomycosis in the immunocompromised patient: a case report36762</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Biomed.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">Absidia</style></keyword><keyword><style  face="normal" font="default" size="100%">acute</style></keyword><keyword><style  face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">Aerosols</style></keyword><keyword><style  face="normal" font="default" size="100%">Agent</style></keyword><keyword><style  face="normal" font="default" size="100%">Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Amphotericin B</style></keyword><keyword><style  face="normal" font="default" size="100%">Amsacrine</style></keyword><keyword><style  face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style  face="normal" font="default" size="100%">Antifungal Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Combined Chemotherapy Protocols</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone Marrow</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">Case</style></keyword><keyword><style  face="normal" font="default" size="100%">case reports</style></keyword><keyword><style  face="normal" font="default" size="100%">Combined Modality Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytarabine</style></keyword><keyword><style  face="normal" font="default" size="100%">Daunorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">Debridement</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance,Fungal</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance,Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Etoposide</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluconazole</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunocompromised Host</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious</style></keyword><keyword><style  face="normal" font="default" size="100%">Institute</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">leukaemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Leukemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Liposomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">microbiology</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Moulds</style></keyword><keyword><style  face="normal" font="default" size="100%">Mucormycosis</style></keyword><keyword><style  face="normal" font="default" size="100%">observed</style></keyword><keyword><style  face="normal" font="default" size="100%">Order</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient</style></keyword><keyword><style  face="normal" font="default" size="100%">patients</style></keyword><keyword><style  face="normal" font="default" size="100%">Print</style></keyword><keyword><style  face="normal" font="default" size="100%">radiography</style></keyword><keyword><style  face="normal" font="default" size="100%">report</style></keyword><keyword><style  face="normal" font="default" size="100%">reports</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">Sinusitis</style></keyword><keyword><style  face="normal" font="default" size="100%">Sites</style></keyword><keyword><style  face="normal" font="default" size="100%">therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">tomography,X-Ray computed</style></keyword><keyword><style  face="normal" font="default" size="100%">Treat</style></keyword><keyword><style  face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/0/2006</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">77 Suppl 2</style></volume><pages><style face="normal" font="default" size="100%">5 - 9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Zygomycosis is a highly aggressive infection observed in immunocompromised patients, such as those with haematological malignancies. The sites most frequently involved are the sinuses and the lungs. New diagnostic tools and new antifungal treatments are essential in order to diagnose early and treat efficiently infections due to moulds. We report a case of sinusitis due to Absidia corymbifera occurring during chemotherapy-induced bone marrow aplasia in a patient with acute leukaemia. The sinusitis was successfully treated with AmBisome, and surgical debridement</style></abstract><custom1><style face="normal" font="default" size="100%">38206</style></custom1><section><style face="normal" font="default" size="100%">5</style></section></record></records></xml>